Scalper1 News
Rockwell Medical (RMTI) stock plummeted to below 10 on the stock market today after an analyst questioned the validity of the firm’s clinical trials, despite another analyst’s rising to the defense. Late Monday, Brean Capital analyst Jonathan Aschoff initiated coverage of the stock with a sell rating and a price target of 4. Rockwell Medical stock was down 25% in midday trading Tuesday, near 10. Aschoff was unimpressed by the recently completed Scalper1 News
Scalper1 News